Summary:
- This article discusses a new once-weekly insulin treatment called Efsitora alfa, developed by the pharmaceutical company Eli Lilly.
- The article reports that in clinical trials, Efsitora alfa was able to significantly reduce participants' A1C levels, which is a measure of average blood sugar over a period of time.
- This new insulin treatment could be a game-changer for people with diabetes, as it only needs to be taken once a week, making it more convenient and potentially improving medication adherence.